Question thread · 2 questions
What consideration is being given to allowing patients living in Edinburgh, Glasgow, Dundee and Aberdeen access to trials in experimental treatment and randomised controlled trials in the treatment of malignant brain tu…
Started with S1W-30879 on 23 Oct 2002; latest 21 Nov 2002. Each later question says it follows up an earlier answer.
Follow-ups
1
Span
29 days
Answered
2 of 2
Asked by
1
The thread, in order
Each answer’s opening lines; open a question for the full text-
To ask the Scottish Executive what consideration is being given to allowing patients living in Edinburgh, Glasgow, Dundee and Aberdeen access to trials in experimental treatment and randomised controlled trials in the treatment of malignant brain tumours.
Malcolm Chisholm, 18 Nov 2002: An additional £1 million has been made available to support the planned Scottish Cancer Research Network (SCRN) which is expected to at least double patient entry into clinical trials. The network is expected to be fully established by April 2003.Participation in clinical trials is subject to patient eligibility again… -
What action has been taken to put in place the tumour-specific multi-disciplinary managed clinical networks for neuro-oncology.
Malcolm Chisholm, 3 Dec 2002: There are three multi-disciplinary neuro-oncology centres in Scotland - one in each Regional Cancer Advisory Group Area - situated in Glasgow (West of Scotland), Edinburgh (South East of Scotland) and Aberdeen (North of Scotland).
How this thread is put together
- Follow-up
- A question whose text says it is “further to the answer to question …” (or reply, response, or asks for a “substantive answer” to an earlier question). The question it names is its parent.
- Several citations
- When a question cites more than one earlier question, the most recent one we hold is used as the parent; the others are listed as “also cites”.
- Thread
- Follow parents back to the first question; every question that leads back to it is in this thread. Branches are shown in date order.